JANX

Janux Therapeutics Stock Analysis

AI Rating

Low
  • Quality2/10
  • Growth↓ 1/10
  • Value↓ 0/10
Janux Therapeutics sales and earnings growth
JANX Growth
Low
  • Revenue Y/Y↑ 47.10%
  • EPS Y/Y↓ -36.30%
  • FCF Y/Y↓ -68.68%
Janux Therapeutics gross and profit margin trends
JANX Profitability
Neutral
  • Gross margin ↑ 100.00%
  • EPS margin↓ -833.60%
  • ROIC 5Y↓ -13.34%
Janux Therapeutics net debt vs free cash flow
JANX Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Janux Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks